Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CONMED Corp Director's Dealing 2013

May 29, 2013

31971_dirs_2013-05-29_0cb7d9e3-cc49-4ed4-a730-56fbe8e60426.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2013-05-28

Reporting Person: Cohen Heather L (VP CORP HR&DEPUTY GEN COUNSEL)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-05-28 Common Stock M 2000 $26.69 Acquired 5687 Direct
2013-05-28 Common Stock F 1726 $34.04 Disposed 3961 Direct
2013-05-28 Common Stock M 2000 $19.26 Acquired 5961 Direct
2013-05-28 Common Stock F 1447 $34.04 Disposed 4514 Direct
2013-05-28 Common Stock S 2522 $34.463 Disposed 1992 Direct
2013-05-28 Common Stock S 1165 $34.616 Disposed 827 Direct
2013-05-29 Common Stock S 827 $33.4374 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-05-28 Sars (Stock Appreciation Rights) $26.69 M 2000 Disposed 2018-06-01 Common Stock (2000) Direct
2013-05-28 Sars (Stock Appreciation Rights) $19.26 M 2000 Disposed 2020-06-01 Common Stock (2000) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.18 to $34.58. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.60 to $34.72. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.36 to $33.51. Full information regarding the number of shares sold at each separate price will be provided upon request of the commission staff, ConMed, or a ConMed security holder.

F4: The stock appreciation rights ("SARs") were granted under the Company's 2006 Stock Incentive Plan and generally vest in equal
amounts over a five year period.

F5: The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.